Concurrent Opioid, Benzodiazepine, and Sedative Burden in an Older Adult
L.C. is a 66-year-old woman with chronic low back pain, generalized anxiety disorder, and major depressive disorder. She lives alone and drives herself. Her medications are oxycodone 10 mg every 6 hours PRN, alprazolam 0.5 mg three times daily, gabapentin 600 mg three times daily, cyclobenzaprine 10 mg three times daily PRN, and sertraline 100 mg daily. Her daughter called the pharmacy concerned that her mother 'fell asleep mid-sentence' twice last week and has had one fall in the bathroom. Reviewing the state prescription drug monitoring program record, you see three different prescribers and two pharmacies in the past 90 days. L.C. says her pain is 'still an 8' and asks whether she can take something stronger.
1. Quantify the sedation and respiratory-depression risk this regimen carries, and identify which components must be addressed first versus which are long-term work.
Read the worked answer
Risk stack: oxycodone (opioid) + alprazolam (benzodiazepine) + gabapentin + cyclobenzaprine + a serotonergic antidepressant. The opioid/benzodiazepine combination carries a well-documented and substantially elevated risk of fatal respiratory depression, and gabapentinoids add dose-related sedation and are frequently implicated in combination overdose deaths. Cyclobenzaprine is sedating and strongly anticholinergic and is among the agents generally avoided in older adults. The clinical signs already present - falling asleep mid-sentence, a bathroom fall - make this an active safety problem, not a theoretical one.
Address first (today): acute sedation and fall risk. Confirm what she actually took and when, screen for confusion, slow or shallow breathing, and orthostatic symptoms, and involve the daughter as a reliable observer. Discuss naloxone and, if the daughter is willing and present, train both of them.
Longer-term work: the sedative burden itself, the antidepressant choice and whether the anxiety is being treated with a benzodiazepine by default, and non-pharmacologic pain and anxiety care. Abrupt discontinuation is not an option - benzodiazepine and opioid cessation both require gradual, prescriber-managed tapering with withdrawal seizure risk if done carelessly.
2. What is your immediate action set during this encounter, and how do you handle the patient's request for a stronger opioid?
Read the worked answer
Immediate actions:
- Do not fill a stronger opioid. Acknowledge the request directly and explain that the priority today is her safety, not her pain score.
- Screen for respiratory depression, oversedation, and recent medication changes, and document findings.
- Provide naloxone with a demonstration and clear instructions to the daughter - this is a same-day intervention, not an optional extra.
- Counsel specifically: no alcohol, no additional sedating OTC sleep aids or antihistamines, no taking the cyclobenzaprine and the alprazolam close together, and no driving while sedated.
- Contact the three prescribers with a factual summary: current regimen, PDMP findings, the two sedation episodes, and the fall. Ask each to confirm what they are prescribing and for a coordinated plan - one prescriber managing opioids, with a taper goal.
On the pain request: reframe it. Her pain intensity is high, but adding opioid potency in a patient who is already falling asleep mid-sentence would increase risk without addressing the likely driver, which is central sensitization, poor sleep, deconditioning, and untreated anxiety. Offer a specific alternative pathway - prescriber discussion of non-opioid adjuvants, physical therapy, and behavioral health - so the 'no' comes with a 'yes, here is the plan.'
3. How do you hold this conversation without destroying the relationship, and what follow-up measure shows it worked?
Read the worked answer
Conversation approach:
- Use motivational interviewing rather than confrontation. Open with her own goals ('You have told me the fall scared you - what would help most?'), reflect, and let her articulate the risk rather than delivering a lecture.
- Be transparent about the PDMP review: tell her what you saw and why you looked. Covert surveillance, once discovered, ends the relationship.
- Separate the medication from the person. The regimen is the problem; she is not being accused of anything.
- Avoid ultimatums about stopping everything at once. Name the one change that is feasible this week and commit to the rest over months.
- Bring the daughter in only with the patient's permission; a perceived loss of autonomy is a common reason older adults disengage from care.
Follow-up measures that demonstrate success:
- No further sedation episodes or falls at 30 and 90 days.
- Naloxone dispensed and, ideally, both patient and daughter able to describe when to use it.
- A single opioid prescriber and a single pharmacy documented in the record.
- Measurable reduction in at least one sedating agent (dose or count) at 90 days, achieved through prescriber taper rather than abrupt stoppage.
- Patient still engaged - she returns calls and keeps appointments. A regimen that improves while the patient disappears from care is a failure.